Literature DB >> 22437810

Embryonic stem cells in safety pharmacology and toxicology.

Tina C Stummann1, Susanne Bremer.   

Abstract

Embryonic stem (ES) cells undergo self-renewal and are pluripotent, i.e., they can give rise to all the types of specialised cells in the body. Scientific knowledge on ES cells is increasing rapidly, leading to opportunities for establishment of ES cell-based in vitro tests for drug discovery, preclinical safety pharmacology and toxicology. The main properties of ES cells making them useful in in vitro assays are that they have a normal diploid karyotype and can provide a large number of cells for high-throughput assays. Human ES cells additionally have the potential to provide solutions to problems related to interspecies differences and methods for screening for human polymorphisms, thus supporting robust human hazard identification and optimised drug discovery strategies. Importantly, ES cell based assays could be potential tools to reduce and perhaps replace, animal experiments. This chapter will describe ongoing research in the use of ES cells in toxicology and safety pharmacology, focusing on the major areas of progress, namely, embryotoxicology, cardiotoxicology and hepatoxicology.

Entities:  

Mesh:

Year:  2012        PMID: 22437810     DOI: 10.1007/978-1-4614-3055-1_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

Review 1.  Use of Zebrafish in Drug Discovery Toxicology.

Authors:  Steven Cassar; Isaac Adatto; Jennifer L Freeman; Joshua T Gamse; Iñaki Iturria; Christian Lawrence; Arantza Muriana; Randall T Peterson; Steven Van Cruchten; Leonard I Zon
Journal:  Chem Res Toxicol       Date:  2019-11-16       Impact factor: 3.739

2.  Effect of ionizing radiation on the proliferation of human embryonic stem cells.

Authors:  Irina V Panyutin; Sonia A Holar; Ronald D Neumann; Igor G Panyutin
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.